Biologic agents, particularly those targeting tumor necrosis factor-alpha (TNF-α), interleukin-17 (IL-17), and interleukin-23 (IL-23), have revolutionized the management of moderate to severe psoriasis [1,2]. The gene discussed is IL17A; the disease is psoriasis.